Kite Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for the Evaluation of Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy as First-Line Treatment for Patients With High-Risk Large B-Cell Lymphoma
凱特公司獲得美國食品藥品監督管理局對Yescarta®（Axicabtagene Ciloleucel）CAR T-細胞療法作爲高風險大B細胞淋巴瘤一線治療評估的再生醫學愛文思控股認證。